PeptideStack
5.2kquestions
20kanswers
220users

My eGFR fell from 85 to 74 eight weeks in. Is that the expected dip or actual injury?

Asked 19 Oct 2024Modified 19 months agoViewed 15k times
32

Male, 52, baseline creatinine 1.05 mg/dL with a reported eGFR of 85. Eight weeks into semaglutide, after two escalations, creatinine 1.18 mg/dL and eGFR 74. No symptoms. I have been drinking normally, had one bad week of nausea around week five with some vomiting but nothing dramatic.

I have read that an early fall in eGFR on this class is expected and haemodynamic rather than harmful, in the same way it is described for SGLT2 inhibitors and ACE inhibitors. I have also read that the drugs cause acute kidney injury through dehydration. Both statements appear in reputable-looking places and they point at opposite conclusions about what I should do.

What I want to know is how to tell them apart from the numbers I have, and what magnitude of fall crosses from "expected" into "investigate". If there is a threshold I would rather know the arithmetic behind it than be told a rule of thumb. And I would like to know whether I can distinguish the two mechanisms without another test, or whether I need something added to the next draw.

kidney-function
kidney-function

eGFR, creatinine, cystatin C and albuminuria: the acute haemodynamic dip that is not injury, the renal outcome data from the FLOW programme, and…

100 questions
bloodwork
bloodwork

Laboratory monitoring: which panels are worth ordering, sensible intervals, reference-range versus optimal-range arguments, and how to read a…

284 questions
hydration
hydration

Fluid intake when thirst and intake cues are both blunted: how much of the early scale drop is fluid, how dehydration confounds a renal panel, and…

14 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
shareeditfollowflag
DO
askedDr_Lena_Ostrowska42k3819 Oct 2024
2What were your urea and electrolytes on the same draw? That is most of the answer. – Dr_Jonas_Halvorsen 7 months ago
The vomiting week matters. A haemodynamic dip and a prerenal insult can coexist and the labs look similar. – rune_thoresen 5 months ago
add a comment

3 Answers

Accepted answer first, then by votes
91

Accepted answer

An 11-point fall from 85 is 13%, which sits comfortably inside the range conventionally treated as an expected haemodynamic dip rather than injury. But the more interesting arithmetic is that your creatinine change may not even be statistically distinguishable from noise, and the mechanism question can largely be settled from analytes that were almost certainly on the same requisition.

First, verify the eGFR arithmetic

The 2021 CKD-EPI creatinine equation:

eGFR = 142 × min(Scr/κ, 1)^α × max(Scr/κ, 1)^(−1.200) × 0.9938^age × 1.012 [if female]

where κ = 0.9 (male), 0.7 (female)
      α = −0.302 (male), −0.241 (female)

For you at baseline, Scr 1.05 mg/dL, male, 52:

  • Scr/κ = 1.05 ÷ 0.9 = 1.1667, which is above 1, so the min term is 1 and only the max term applies.
  • 1.1667^(−1.200): ln(1.1667) = 0.15415; × (−1.200) = −0.18498; exp(−0.18498) = 0.8311.
  • 0.9938^52: ln(0.9938) = −0.006219; × 52 = −0.32339; exp(−0.32339) = 0.7237.
  • eGFR = 142 × 0.8311 × 0.7237 = 142 × 0.6014 = 85.4 mL/min/1.73 m².

At the follow-up, Scr 1.18:

  • Scr/κ = 1.18 ÷ 0.9 = 1.3111. ln = 0.27092; × (−1.200) = −0.32510; exp = 0.7224.
  • eGFR = 142 × 0.7224 × 0.7237 = 142 × 0.5228 = 74.2 mL/min/1.73 m².

So the reported numbers are right: a fall of 11.2 units, 13.1% of baseline.

The part that should give you pause about over-reading it

Your creatinine rose from 1.05 to 1.18 mg/dL, a change of 12.4%. The reference change value for creatinine, combining an analytical CV of about 3% with a within-person biological CV of about 5%, is 2.77 × sqrt(9 + 25) = 2.77 × 5.83 = 16%.

Your 12.4% is below that, so formally a single pair differing by 12% does not establish that anything changed. The eGFR difference of 13 percentage points looks more alarming because the equation is non-linear and amplifies small creatinine movements into larger-looking eGFR movements — worth knowing generally, since it is the source of most eGFR panic.

For contrast, had the follow-up been 1.30 mg/dL, that is a 23.8% rise, which clears the RCV: 1.30 ÷ 0.9 = 1.4444; ln = 0.36772; × (−1.2) = −0.44127; exp = 0.6433; eGFR = 142 × 0.6433 × 0.7237 = 66.1. A fall of 22% — still inside the conventional tolerance band, but now genuinely measured.

The threshold, and where it comes from

The widely used heuristic is that a fall of up to about 30% of baseline eGFR, occurring early and then stabilising, does not warrant stopping the drug, whereas a larger or progressive fall warrants investigation.

Be clear about the provenance: that figure was established in the renin-angiotensin blockade literature and carried across to SGLT2 inhibitors, where continuing through the dip is associated with better long-term outcomes than stopping. It has not been formally established for GLP-1 receptor agonists, where the acute dip is smaller and less consistent. Borrowing it is reasonable and it is a borrowing.

Mechanism: what the dip actually is

In hyperfiltration — common with obesity and with diabetes — single-nephron GFR is elevated by raised intraglomerular pressure, which is damaging over years. Reduce that pressure and measured GFR falls immediately while the nephron is being protected. Contributory mechanisms in this class include natriuresis, inhibition of proximal tubular sodium-hydrogen exchange increasing distal sodium delivery, activation of tubuloglomerular feedback with afferent arteriolar constriction, plus reduced systemic blood pressure and reduced glomerular hypertrophy as weight falls.

So a dip is a marker of the drug acting on the relevant lever, not of harm. This is why slope analyses in this class are usually presented both from baseline and from a post-initiation reference point — the acute dip drags the from-baseline figure down and understates the chronic benefit [1].

Telling it apart from a prerenal insult, from data you probably already have

A haemodynamic dip and volume depletion both raise creatinine. They differ in what else moves. Check these on the same draw:

  • Urea (BUN) relative to creatinine. In volume depletion urea rises proportionally more, because low tubular flow increases passive urea reabsorption. In US units a BUN:creatinine ratio above roughly 20:1 points prerenal; below 15:1 argues against. In SI, urea in mmol/L divided by creatinine in µmol/L times 1000 gives a comparable index, above about 100 suggesting prerenal. A pure haemodynamic dip barely disturbs the ratio.
  • Haematocrit, haemoglobin and albumin. All three rise with haemoconcentration. If albumin went from 41 to 45 g/L and haematocrit rose alongside the creatinine, you were dry.
  • Sodium and bicarbonate. Vomiting produces a hypochloraemic, hypokalaemic picture with raised bicarbonate; diarrhoea does the opposite to bicarbonate. Either points at GI fluid loss.
  • Time course. A haemodynamic dip appears in the first few weeks then plateaus. A prerenal insult tracks the GI episode and resolves within a week or two of it ending.

Your week-five vomiting is what makes this worth checking rather than assuming. If the draw was within a fortnight of that episode, repeat creatinine and electrolytes after two to three weeks of normal eating and drinking. If it returns towards 1.05 you had a transient prerenal component; if it sits at 1.18 you have a new steady state, which is what a haemodynamic dip looks like.

What would change the answer: a continuing rise across three draws, a fall beyond 30% of baseline, new albuminuria, hyperkalaemia, or symptoms. Those belong with a clinician, not a spreadsheet.

edited 2 Dec 2024 by cold_lane — removed a claim I could not source

shareimprove this answerflag
CL
answered · acceptedcold_lane14k1830 Nov 2024
The observation that the eGFR equation amplifies small creatinine changes into scarier-looking eGFR changes explains a lot of panic. – Dr_Signe_Baldursdottir 26 days ago
Pointing out that the 30% rule is borrowed from the RAS-blockade and SGLT2 literature rather than established for this class is the honest caveat. – juan_esquivel 9 months ago
3Urea:creatinine ratio plus albumin and haematocrit on the same draw is a free volume assessment. – Dr_Nadia_Farsi 8 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
39

Adding the dehydration side of the picture properly, because the second thing you read is also true and the two claims are not actually in conflict — they describe different events with different time courses.

The two things that happen

The haemodynamic dip is a pharmacological effect, appears in the first weeks, is small, plateaus, and is associated with better long-term trajectory. It is not injury.

Volume-depletion acute kidney injury is a complication of the gastrointestinal side effects, not of receptor activation. It happens when someone vomits for days, cannot keep fluids down, and keeps taking their diuretic, ACE inhibitor or ARB and their non-steroidal anti-inflammatory. It appears when the GI episode appears, and it can be severe. Post-marketing reports of acute kidney injury in this class are dominated by exactly this scenario, and the labels reflect it: the warning is about dehydration secondary to gastrointestinal adverse reactions rather than about a direct nephrotoxic mechanism.

So the risk profile is not "this drug damages kidneys". It is "this drug can make you unable to drink, and being unable to drink damages kidneys". That distinction changes what you do about it entirely.

The interaction that does the damage

The recognised high-risk combination is volume depletion plus agents that remove the kidney's compensatory mechanisms:

  • Diuretics — reduce the volume you had left to lose.
  • ACE inhibitors or ARBs — block angiotensin II-mediated efferent constriction, which is precisely what maintains filtration pressure during hypovolaemia.
  • NSAIDs — block prostaglandin-mediated afferent dilatation, the other compensatory arm.

Any two of those with an intercurrent vomiting illness is the classic setup, and it is not specific to this drug class — it is the same mechanism that causes acute kidney injury during gastroenteritis in older patients on polypharmacy. What is specific is that this class induces the vomiting rather than encountering it by chance, and does so most often in the days after an escalation.

The practical implication

Many clinicians operate an explicit plan for this, sometimes called sick-day guidance: during an episode of significant vomiting or diarrhoea, certain medications are temporarily held. Which ones, and for how long, is a decision for whoever prescribed them, and this is one of the genuinely important reasons to have a prescriber who knows your full medication list rather than a supply chain. If you take any of the three categories above and you have not had that conversation, it is the highest-value conversation available to you in this whole area.

On the arithmetic of when to worry: the KDIGO staging for acute kidney injury uses a creatinine rise of 0.3 mg/dL (26.5 µmol/L) within 48 hours, or a 1.5-fold rise from baseline within seven days, as stage 1. Your 1.05 to 1.18 is a rise of 0.13 mg/dL over eight weeks, which is not close to those criteria on either magnitude or rate. That framing is more useful than the eGFR percentage because it separates a slow settling to a new set point from an acute event.

shareimprove this answerflag
DV
answereddead_volume49k3819 Nov 2024
7The reframing from "the drug damages kidneys" to "the drug can stop you drinking" is exactly right and changes the mitigation. – tenth_of_a_unit 3 months ago
8Triple whammy of diuretic, ARB and NSAID during a vomiting week is the actual mechanism in most of the case reports. – Dr_Hanne_Solberg 4 months ago
add a comment
18

One measurement point that will save you a repeat draw: ask for cystatin C on the next sample, and ask for the urine albumin:creatinine ratio at the same time.

The reason is that creatinine-based eGFR is about to become unreliable for you in a specific direction. Creatinine is generated from muscle, so as lean mass falls during weight loss, creatinine production falls and creatinine-based eGFR drifts upwards independently of any change in filtration. Over the next six to twelve months that drift will partly or wholly cancel your haemodynamic dip, and you will be unable to tell whether your kidney function recovered, deteriorated, or stayed flat while your muscle mass changed underneath the measurement.

Cystatin C is produced by all nucleated cells at a fairly constant rate and is not muscle-dependent, so an eGFR derived from it is immune to that particular confounder. If you have both on the same sample, you can compute the combined creatinine-cystatin C eGFR, which is the most accurate of the three, and you can also use the discordance between the two single-marker estimates as information in its own right.

Albuminuria is worth adding for a different reason: it measures damage rather than filtration, and it moves for reasons the eGFR does not. In the situation you are describing — an early eGFR dip of uncertain significance — a normal and stable albumin:creatinine ratio is substantially more reassuring than any single eGFR value, and a rising one would be the finding that changes the conversation. It costs almost nothing, requires only a spot urine sample, and is the single most under-ordered kidney test in this population.

Do both on the same visit as your repeat creatinine, and you turn one ambiguous data point into a picture with three independent lines of evidence.

shareimprove this answerflag
M4
answeredmz_411399k25822 Dec 2024

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.